Genmab — Juni 2016
-
Slide paa fase 1b studie i subcut daratumumab http://files.shareholder.com/downloads/AMDA-KPIBN/2038929137x0x895421/DAEC0853-9289-469A-ABC5-4F65429069E7/2016_ASCO_DARA_Ph_IB_sc_MM_PAVO_Nahi_poster_FINAL.pdf
-
Biogen (-12%) får godt nok trukket NBI (-2%) ned
-
Lidt mere om Halozyme - positivt phase 2 resultat http://seekingalpha.com/news/3187290-halozymes-lead-product-candidate-pegph20-shows-positive-results-mid-stage-study-pancreatic?source=email_rt_mc_readmore&uprof=45&dr=1#email_link
-
-
Interessant nok, så er det i MS at Biogen fejler....
-
-
Citat fundet online: Genmab has publicly and repeatedly confirmed that Daratumuma
b benefits from tiered royalties. The royalty range has been indicated to run all the way up to the “high-twenty-something-percent”. - Troede at royalties cappede ved 20 %?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind